San Luis Wealth Advisors’s Moderna MRNA Stock Holding History

San Luis Wealth Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-28	Closed	-$7K	–	296
2022 Q1	$7K	Buy	+28	New	+$4.71K	﹤0.01%	385

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

San Luis Wealth Advisors's MRNA Position: Q2 2022 in Review

San Luis Wealth Advisors sold out of Moderna (MRNA) in Q2 2022, closing a stake of 28 shares — an estimated $7K sold.

San Luis Wealth Advisors first reported a position in MRNA in Q1 2022 and held it in 1 quarter. The position peaked at $7K in Q1 2022. 981 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

San Luis Wealth Advisors reported no remaining Moderna position as of Q2 2022 after selling out during the quarter.
San Luis Wealth Advisors sold 28 Moderna shares in Q2 2022, an estimated $7K.
San Luis Wealth Advisors first reported a position in Moderna in Q1 2022 and held it in 1 quarter.
San Luis Wealth Advisors's Moderna position peaked at $7K in Q1 2022.
981 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on San Luis Wealth Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.